Home Ingredients FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)
Menopause SupportWomen's Health

FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)

Trigonella foenum-graecum
Evidence Level
Strong
2 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

FenuSmart® (also spelled FenuSMART™) is Akay Bioactives' standardized fenugreek (Trigonella foenum-graecum) husk extract — featuring a unique 3:1 (w/w) ratio of protodioscin to trigonelline (saponin and alkaloid bioactives). Supported by 5 clinical studies and 2 US patents. In postmenopausal women, 1,000 mg/day raised plasma estradiol and reduced hot flashes, night sweats, mood swings, sleeplessness, irritability, and vaginal dryness vs placebo; a lower 500 mg/day dose also showed efficacy. Honest framing: substantial clinical evidence base for menopausal symptom support, with the estradiol elevation mechanism distinguishing FenuSmart from purely phytoestrogen-based menopause supplements. Akay-funded but published in peer-reviewed journals.

Studied Dose 1,000 mg/day; lower-dose protocol 250 mg twice daily (500 mg/day).
Active Compound Trigonella foenum-graecum (fenugreek) husk extract standardized to protodioscin and trigonelline at 3:1 (w/w) (steroidal saponins + alkaloids).

Benefits

120% increase in plasma estradiol (Shamshad Begum 2016)

Randomized double-blind placebo-controlled trial in women with moderate-severe postmenopausal symptoms: 1,000 mg/day FenuSmart increased plasma estradiol by 120% (p<0.01) vs baseline and placebo (from 131.22 to 288.46 pmol/L mean). Critical mechanism distinguishing FenuSmart — actual endogenous estradiol elevation rather than just symptomatic relief or phytoestrogen activity.

Supported by Trial 1, Trial 2

Hot flash reduction (47.8% severity, 32% elimination)

32% of subjects reported NO hot flashes after supplementation; remaining subjects reduced from 3-5 hot flashes/day at baseline to 1-2/day. Overall hot flash severity reduction: 47.8% vs placebo. Hot flashes are the most disruptive symptom for many menopausal women and a primary outcome for non-hormonal menopause therapies.

Supported by Trial 1, Trial 2

Sleep and mood improvements

Multi-symptom improvements documented: night sweats -53%, sleeplessness -71%, mood swings -69%, irritability -76%, apprehensiveness -60%, headaches -46%. Captures the constellation of menopausal symptoms beyond vasomotor events — recognizing that menopause affects sleep, mood, and cognition alongside hot flashes.

Supported by Trial 1

Vaginal moisture restoration

Vaginal dryness — a frequent and underreported menopausal symptom — decreased 56.3% in the FenuSmart group. Practical relevance for menopause-related sexual health and quality of life. Effect likely mediated by the estradiol elevation since vaginal tissue is highly estrogen-responsive.

Supported by Trial 1, Trial 2

Lipid profile maintenance

While placebo subjects showed expected age/menopause-related increases in total cholesterol, LDL, and triglycerides, FenuSmart subjects maintained baseline lipid levels — suggesting plausible cardiovascular benefit. Important because menopause is associated with adverse lipid changes that increase cardiovascular risk.

Supported by Trial 1

Low-dose efficacy at 500 mg/day

A 500 mg/day total dose (250 mg twice daily) also produced significant menopausal symptom improvements in post-menopausal women. Allows lower-dose protocol for milder symptom profiles or budget-conscious formulations.

Supported by Trial 2

Mechanism of action

1

Endogenous estradiol elevation

Mechanism distinct from phytoestrogen activity (where the supplement binds estrogen receptors). FenuSmart's protodioscin appears to support endogenous estradiol synthesis — measured as 120% increase in plasma estradiol over 90 days. Likely operates via DHEA precursor pool support and/or aromatase pathway modulation.

2

Saponin/alkaloid synergy

The 3:1 protodioscin:trigonelline ratio is specification-controlled because the two bioactive classes appear to work synergistically — neither alone produces the full FenuSmart effect profile. This is why undefined fenugreek extracts produce variable clinical results across studies.

3

Vasomotor stability

Restored estradiol levels stabilize the hypothalamic thermoregulatory center, reducing the labile temperature setpoint that drives hot flashes and night sweats. Same downstream mechanism as hormone replacement therapy but via endogenous estradiol elevation rather than exogenous hormone administration.

4

Lipid metabolism support

Restored estradiol levels maintain favorable lipid profile (estrogen has well-established beneficial effects on HDL elevation and LDL reduction). Explains the FenuSmart group's stable lipid markers vs placebo group's expected adverse changes.

Clinical trials

1
FenuSmart 1,000 mg Menopause Trial — Shamshad

Randomized double-blind placebo-controlled trial in 88 women with moderate-severe postmenopausal symptoms (Greene Climacteric Scale, SF-36 quality-of-life testing). Intervention: 1,000 mg/day FenuSmart or placebo for 90 days.

88 women with moderate-severe postmenopausal symptoms (Greene Climacteric Scale

Randomized double-blind placebo-controlled trial in 88 women with moderate-severe postmenopausal symptoms (Greene Climacteric Scale, SF-36 quality-of-life testing). Intervention: 1,000 mg/day FenuSmart or placebo for 90 days. Outcomes: estradiol +120% (p<0.01); hot flashes eliminated in 32%; reduced 47.8% severity in remainder; night sweats -53%; mood swings -69%; sleeplessness -71%; irritability -76%; apprehensiveness -60%; headaches -46%; vaginal dryness -56.3%. Lipid profile maintained vs placebo deterioration. Published in Phytother Res 2016.

2
FenuSmart Low-Dose Validation

Randomized double-blind placebo-controlled trial in 48 post-menopausal women (average age 54). Intervention: 250 mg × 2/day (500 mg/day total) FenuSmart for 6 weeks.

Clinical population described in trial publication.

Randomized double-blind placebo-controlled trial in 48 post-menopausal women (average age 54). Intervention: 250 mg × 2/day (500 mg/day total) FenuSmart for 6 weeks. Outcomes: significant menopausal symptom improvements and hormonal balance support at this lower dose. DHEA (precursor to androgens and estrogens) elevation contributed to mechanism. Supports flexible dosing options for varying symptom severity profiles.

Side effects and drug interactions

Common Potential side effects

Well-tolerated in 90-day trial; no adverse hematological, biochemical, or clinical effects.
Maple-syrup body odor possible at high fenugreek doses (a characteristic fenugreek effect, harmless).
Possible mild GI effects (gas, bloating) at higher doses.
Fenugreek allergy contraindication — also cross-reacts with peanut and chickpea allergies in some individuals.
Pregnancy: avoid — fenugreek is traditionally used to stimulate uterine activity and may pose miscarriage/preterm risk. Lactation: traditionally used as galactagogue but supplemental doses warrant clinician consultation.

Important Drug interactions

Anticoagulants — fenugreek contains coumarin-like compounds; monitor INR with warfarin.
Antidiabetic medications — fenugreek modestly lowers blood glucose; monitor and adjust diabetes medications.
Hormone replacement therapy — additive estrogenic effect; consult prescriber.
Hormone-sensitive conditions (estrogen receptor-positive breast cancer, endometriosis, fibroids) — caution due to estradiol-elevating mechanism.
Pregnancy: avoid. Lactation: consult clinician despite traditional galactagogue use.

Featured in these supplement guides

Menopause Symptoms→

More Menopause Support Ingredients

Menopause Support
Black Cohosh (Actaea racemosa)
Black cohosh is a flowering plant native to eastern North America whose root extract has b…
Menopause Support
EstroG-100® (Phytoestrogen Complex)
EstroG-100® (Naturalendo Tech Co.) is a patented, standardized extract combining three tra…
Menopause Support
Lifenol™ (Standardized Hop Extract for Menopause — Givaudan)
Lifenol™ is Givaudan's patented polyphenolic extract from female Humulus lupulus (hop) flo…
Menopause Support
Hop Extract (Humulus lupulus) for Menopause
Hop extract from Humulus lupulus (the hop plant, source of beer bittering) is one of the m…

Explore Other Ingredients

Sleep Health
5-HTP (5-hydroxytryptophan)
5-Hydroxytryptophan (5-HTP) is a naturally occurring compound derived from L-tryptophan, s…
Sleep Health
GABA
GABA (gamma-aminobutyric acid) is the body's main calming, inhibitory neurotransmitter, an…
Sleep Health
Melatonin
Melatonin is a hormone produced by the pineal gland that regulates circadian rhythm and si…

Frequently asked questions about FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)

What is FenuSmart?

FenuSmart® (also spelled FenuSMART™) is Akay Bioactives' standardized fenugreek (Trigonella foenum-graecum) husk extract — featuring a unique 3:1 (w/w) ratio of protodioscin to trigonelline (saponin and alkaloid bioactives). Supported by 5 clinical studies and 2 US patents.

What is FenuSmart used for?

FenuSmart is researched primarily for Menopause Support and Women's Health. Randomized double-blind placebo-controlled trial in women with moderate-severe postmenopausal symptoms: 1,000 mg/day FenuSmart increased plasma estradiol by 120% (p<0.01) vs baseline and placebo (from 131.22 to 288.46 pmol/L mean).

What is the recommended dosage of FenuSmart?

The clinically studied dose is 1,000 mg/day; lower-dose protocol 250 mg twice daily (500 mg/day). Always follow the product label and check with a healthcare provider for personal advice.

Is FenuSmart safe, and does it have side effects?

For most healthy adults, FenuSmart is well tolerated at studied doses. Reported effects can include: Well-tolerated in 90-day trial; no adverse hematological, biochemical, or clinical effects. Maple-syrup body odor possible at high fenugreek doses (a characteristic fenugreek effect, harmless). It may also interact with some medications. FenuSmart is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does FenuSmart interact with any medications?

Possible interactions include: Anticoagulants — fenugreek contains coumarin-like compounds; monitor INR with warfarin. Antidiabetic medications — fenugreek modestly lowers blood glucose; monitor and adjust diabetes medications. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for FenuSmart?

NutraSmarts rates the evidence for FenuSmart as Strong (4 out of 5). It is backed by 2 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Shamshad Begum S, Jayalakshmi HK, Vidyavathi HG, Gopakumar G, Abin I, Balu M, et al. A Novel Extract of Fenugreek Husk (FenuSMART) Alleviates Postmenopausal Symptoms and Helps to Establish the Hormonal Balance: A Randomized, Double-Blind, Placebo-Controlled Study. Phytother Res. 2016;30(11):1775-1784. doi: 10.1002/ptr.5680.PubMedUsed to support: The pivotal RCT for this ingredient: 88 postmenopausal women given FenuSMART 1000 mg/day for 90 days showed significant rises in plasma estradiol and reduced hot flashes and other discomforts versus placebo, backing the menopausal-symptom and hormonal-balance claims; industry-funded, single small site.
  2. Khanna A, John F, Das S, Thomas J, Rao J, Maliakel B, et al. Efficacy of a novel extract of fenugreek seeds in alleviating vasomotor symptoms and depression in perimenopausal women: A randomized, double-blinded, placebo-controlled study. J Food Biochem. 2020;44(12):e13507. doi: 10.1111/jfbc.13507.PubMedUsed to support: Small RCT (n=48) of fenugreek husk extract 250 mg twice daily for 42 days in perimenopausal women found significant improvement in hot flashes, night sweats, depression and insomnia plus increased estradiol/progesterone and lower FSH versus placebo; supports the perimenopausal-symptom claim but is small and industry-funded.
  3. Sureshkumar D, Begum S, Johannah NM, Maliakel B, Krishnakumar IM. Toxicological evaluation of a saponin-rich standardized extract of fenugreek seeds (FenuSMART): Acute, sub-chronic and genotoxicity studies. Toxicol Rep. 2018;5:1060-1068. doi: 10.1016/j.toxrep.2018.10.008.PubMedUsed to support: Animal/in-vitro safety dossier for FenuSMART reporting no acute, sub-chronic, or genotoxic effects up to the highest dose tested, supporting tolerability/safety rather than any efficacy claim; preclinical and industry-funded.